Treatment methods having reduced drug-related toxicity and methods of identifying the likelihood of patient harm from prescribed medications
AssigneeTabula Rasa Healthcare, Inc.
InventorsJacques Turgeon, Lauren E. Steffen, Gabriel Badea, Veronique Michaud
Life of this patent
Estimating the term…
Abstract
Methods of determining whether specific drugs or patients carry an increased risk of causing or developing, respectively, long QT syndrome or Torsades de Pointes and methods of treating such patients.
Claims11
A method for determining a propensity of a medication for causing long QT syndrome or Torsades de Pointes by determining a drug-specific index for the medication, the method comprising the steps of:
- calculating a first index variable for the medication by determining:
- an IC50 value for block of one or more of IKr and IKs for the medication, a Cmax of the medication at a test dose, a daily dose amount of the medication, a protein binding value for the medication at a target protein, and a drug-drug interaction coefficient (DDIC) for the medication;
- measuring calculating a second index variable for the medication by determining:
- an IC50 value for block of CaV1.2 current for the medication, and
- the IC50 value for block of one or more of IKr and IKs for the medication;
- calculating a third index variable for the medication by determining:
- an IC50 value for block of NaV1.5 current for the medication, and the IC50 value for block of one or more of IKr and IKs for the medication;
- calculating a fourth index variable for the medication based on whether the medication is an inhibitor of hERG trafficking;
- and
- combining the first, second, third, and fourth index variables to provide the drug-specific index, which is indicative of the medication's risk of causing long QT syndrome or Torsades de Pointes.
A method for determining whether a patient undergoing treatment with a compound has an increased risk of long QT syndrome or Torsades de Pointes by determining a patient-specific score, the method comprising one or more steps of:
- (a) determining a first risk variable value based on the patient's gender and age;
- (b) measuring the patient's heart rhythm comprising detecting one or more of sinus rhythm, atrial fibrillation, sick sinus syndrome, pause, and heart rate to generate a second risk variable value;
- (c) detecting a potassium level in the patient to generate a third risk variable value;
- (d) detecting a magnesium level in the patient to generate a fourth risk variable value;
- (e) detecting the presence of one or more diuretics in the patient to generate a fifth risk variable value;
- (f) detecting the presence of one or more antiarrhythmics in the patient to generate a sixth risk variable value;
- (g) measuring a drug-specific index for one or more drug therapeutics in the patient's treatment regimen to generate a seventh risk variable value;
- and
- (h) measuring the patient's QT interval to generate an eight risk variable value, and
- the method further comprising combining the determined risk variable values from the one or more of steps (a) through (h) to obtain a patient-specific score, wherein a patient-specific score under a predetermined threshold value is indicative of the patient having an increased risk of long QT syndrome and/or Torsades de Pointes.
A method of treating patients having an increased risk of developing long QT syndrome or Torsades de Pointes due to a patient-specific score exceeding a predetermined threshold value, the method comprising administering a therapeutically effective amount of a medication.
(canceled)
Dependencies are inferred from the claim text.